Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03815682 · ClinicalTrials.gov registry record · Phase 1
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
A Phase 1 study, sponsored by Repertoire Immune Medicines.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03815682 is a Phase 1 study that was terminated before completion, run by Repertoire Immune Medicines. The registered enrollment target is 23 participants.
The verdict
NCT03815682, a Phase 1 study, was terminated before completion, sponsored by Repertoire Immune Medicines.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors and lymphomas.
Interventions
- BIOLOGICAL Arm A: RPTR-147:1
- BIOLOGICAL Arm B: RPTR-147:1 and Pembrolizumab
- BIOLOGICAL Arm C: RPTR-147:2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-10-24 |
| Est. Completion | 2022-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03815682
The ClinicalTrials.gov registry entry for NCT03815682 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repertoire Immune Medicines, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Arm A: RPTR-147:1 is the first listed.
NCT03815682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03815682 about?
NCT03815682 is a clinical study titled "RPTR-147 in Patients With Selected Solid Tumors and Lymphomas". The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors and lymphomas.
What is the current status of trial NCT03815682?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2018-10-24. Estimated completion is 2022-10-11.
What interventions are being tested in trial NCT03815682?
The interventions under investigation include: Arm A: RPTR-147:1 (BIOLOGICAL), Arm B: RPTR-147:1 and Pembrolizumab (BIOLOGICAL), Arm C: RPTR-147:2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03815682?
This trial is sponsored by Repertoire Immune Medicines, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.